Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286485 | 0.84 | TSHR (0.50) | TDP1TSHRCYP3A4MAPK1ALDH3A1 | |
| SCHEMBL22897851 | 0.83 | TDP1 (0.49) | TDP1TSHRCYP3A4MAPK1ALDH3A1 | |
| SCHEMBL22115093 | 0.83 | TSHR (0.51) | TDP1TSHRCYP3A4MAPK1ALDH3A1 | |
| SCHEMBL29560800 | 0.83 | TDP1 (0.49) | TDP1TSHRCYP3A4MAPK1ALDH3A1 | |
| SCHEMBL3054634 | 0.81 | MAPT (0.63) | TDP1TSHRCYP3A4MAPK1ALDH3A1 | |
| SCHEMBL12848080 | 0.80 | PDK1 (0.51) | TDP1TSHRALDH3A1HCAR3ALDH1A1 | |
| SCHEMBL3053127 | 0.79 | HCAR3 (0.49) | TDP1TSHRCYP3A4MAPK1ALDH3A1 | |
| SCHEMBL3054662 | 0.79 | VCAM1 (0.51) | TDP1TSHRCYP3A4MAPK1ALDH3A1 | |
| SCHEMBL22897786 | 0.78 | HCAR3 (0.45) | TDP1TSHRCYP3A4MAPK1ALDH3A1 | |
| SCHEMBL27737624 | 0.77 | ALDH1A1 (0.59) | TDP1TSHRCYP3A4MAPK1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714009-B2 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135452-A1 | Nitrogen-containing fused heterocyclic compounds | NPY4R, NR4A3, NR3C2 | TDP1 4581/4885TSHR 278/4885CYP3A4 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.